Solventum Corporation (NYSE:SOLV) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

Key Points

• Analysts rate Solventum a “Moderate Buy,” with eight buy ratings, three holds and one sell among 12 analysts. The average 12-month price target is $92.80, above the reported $89.60 share price.
• Solventum reported quarterly EPS of $2.55, beating consensus estimates of $1.91, while revenue reached $2.21 billion and rose 2.2% year over year.
• The stock has gained momentum, trading near its 12-month high of $94.16, while several institutional investors increased their holdings during the second quarter.

Shares of Solventum Corporation (NYSE:SOLV - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twelve analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $92.80.

A number of brokerages have commented on SOLV. BTIG Research reiterated a "buy" rating and set a $95.00 price target on shares of Solventum in a research report on Monday, September 14th. Weiss Ratings upgraded shares of Solventum from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, August 18th. Mizuho set a $113.00 price objective on shares of Solventum in a report on Thursday, August 6th. UBS Group upped their price objective on shares of Solventum from $95.00 to $101.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Finally, BMO Capital Markets initiated coverage on shares of Solventum in a report on Wednesday, July 8th. They set a "market perform" rating and a $81.00 target price on the stock.

Institutional Trading of Solventum

Institutional investors have recently added to or reduced their stakes in the business. Sequoia Financial Advisors LLC grew its stake in shares of Solventum by 18.7% during the second quarter. Sequoia Financial Advisors LLC now owns 21,672 shares of the company's stock valued at $1,672,000 after buying an additional 3,412 shares during the last quarter. MCF Advisors LLC lifted its stake in shares of Solventum by 2,497.7% in the 2nd quarter. MCF Advisors LLC now owns 1,143 shares of the company's stock valued at $88,000 after acquiring an additional 1,099 shares during the last quarter. WINTON GROUP Ltd bought a new stake in shares of Solventum in the 2nd quarter valued at about $3,402,000. Engineers Gate Manager LP purchased a new stake in Solventum during the 2nd quarter valued at about $1,881,000. Finally, Integrated Wealth Concepts LLC boosted its holdings in Solventum by 7.1% during the 2nd quarter. Integrated Wealth Concepts LLC now owns 9,052 shares of the company's stock valued at $698,000 after acquiring an additional 597 shares during the period.

Solventum Price Performance

SOLV opened at $89.60 on Friday. The stock has a 50-day moving average price of $87.39 and a 200-day moving average price of $77.69. Solventum has a 12-month low of $62.38 and a 12-month high of $94.16. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 1.00. The stock has a market capitalization of $15.25 billion, a P/E ratio of 10.95, a PEG ratio of 1.40 and a beta of 0.61.

Solventum (NYSE:SOLV - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, beating the consensus estimate of $1.91 by $0.64. The firm had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The company's revenue was up 2.2% on a year-over-year basis. During the same period in the prior year, the company earned $1.69 EPS. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Equities analysts predict that Solventum will post 7.22 earnings per share for the current fiscal year.

About Solventum

Solventum Corporation NYSE: SOLV is a global healthcare company that develops products and technologies intended to improve patient care, support healthcare professionals and increase the efficiency of healthcare delivery. The company serves hospitals, clinics, dental practices, laboratories, government agencies and other healthcare-related organizations.

Its offerings include medical and surgical products such as wound-care, skin-care, infection-prevention and surgical solutions; dental products and materials; and health information systems that support clinical documentation, coding, workflow and decision-making.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.